Clinical protocol
RTOG 0615 protocol — A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal Cancer
NRG Oncology / RTOG
DoseLab summary
NRG Oncology's page for RTOG 0615, a phase 2 trial of concurrent chemoradiotherapy with IMRT (or 3D-CRT) plus bevacizumab for locally or regionally advanced nasopharyngeal cancer. The protocol document lists planning goals for head and neck organs. The larynx and cochlea values in DoseLab's head and neck table are credited to it in the compiling protocol; DoseLab could not extract readable text from the protocol copy it found, so these values have not yet been checked against the protocol itself.
Why this is useful
An RTOG nasopharynx IMRT protocol whose organ goals — larynx and cochlea among them — are quoted in head and neck constraint tables.
Reference details
- Title
- RTOG 0615 protocol — A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal Cancer
- Authors / organization
- NRG Oncology / RTOG
- Publication / protocol
- Protocol document, RTOG 0615
- Version
- Pending verification
- Year
- 2006
- DOI
- Pending verification
- Disease sites
- Head & Neck
- Topics
- Head & Neck, Nasopharynx, Dose Constraints, Protocols, RTOG, NRG, IMRT
- Fractionation context
- Conventional fractionation with concurrent chemotherapy
- Last reviewed by DoseLab
- Pending verification